Healthcare provider profile · identity verified

Whitney Kaefring, MD

Family Practice · MUSCATINE, IA · NPI 1548619349

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	161	62
Levothyroxine Sodium	Levothyroxine Sodium	133	32
Lisinopril	Lisinopril	93	26
Omeprazole	Omeprazole	93	27
Furosemide	Furosemide	81	24
Gabapentin	Gabapentin	78	23
Rosuvastatin Calcium	Rosuvastatin Calcium	72	21
Amlodipine Besylate	Amlodipine Besylate	71	28
Hydrochlorothiazide	Hydrochlorothiazide	71	23
Metformin Hcl Er	Metformin Hcl	68	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	66	17
Famotidine	Famotidine	62	20
Albuterol Sulfate Hfa	Albuterol Sulfate	57	26
Losartan Potassium	Losartan Potassium	54	17
Pregabalin	Pregabalin	54	11
Metoprolol Tartrate	Metoprolol Tartrate	52	16
Escitalopram Oxalate	Escitalopram Oxalate	46	15
Fluticasone Propionate	Fluticasone Propionate	45	14
Pantoprazole Sodium	Pantoprazole Sodium	45	16
Metformin Hcl	Metformin Hcl	40	14
Tamsulosin Hcl	Tamsulosin Hcl	39	12
Duloxetine Hcl	Duloxetine Hcl	35	15
Potassium Chloride	Potassium Chloride	35	13
Trazodone Hcl	Trazodone Hcl	35	14
Metoprolol Succinate	Metoprolol Succinate	34	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Simvastatin	Simvastatin	30	suppressed
Ozempic	Semaglutide	29	suppressed
Clopidogrel	Clopidogrel Bisulfate	27	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	26	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	25	suppressed
Dexlansoprazole Dr	Dexlansoprazole	24	suppressed
Atenolol	Atenolol	23	suppressed
Meloxicam	Meloxicam	23	suppressed
Sertraline Hcl	Sertraline Hcl	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Trulicity	Dulaglutide	23	suppressed
Carvedilol	Carvedilol	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Alendronate Sodium	Alendronate Sodium	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Tramadol Hcl	Tramadol Hcl	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Benazepril Hcl	Benazepril Hcl	18	suppressed
Montelukast Sodium	Montelukast Sodium	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Ibuprofen	Ibuprofen	15	suppressed
Pravastatin Sodium	Pravastatin Sodium	15	suppressed
Alprazolam	Alprazolam	14	suppressed
Eliquis	Apixaban	14	suppressed
Finasteride	Finasteride	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Allopurinol	Allopurinol	13	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Haloperidol	Haloperidol	13	suppressed
Jardiance	Empagliflozin	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Folic Acid	Folic Acid	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Imipramine Hcl	Imipramine Hcl	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Topiramate	Topiramate	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error